Go to the list of all blogs
Sergey Savastiouk's Avatar
published in Blogs
Sep 23, 2026
Why Is IM Cannabis (IMCC) Stock Down -30.19% Today?

Why Is IM Cannabis (IMCC) Stock Down -30.19% Today?

Key Takeaways

  • Shares of IMCC plunged roughly 30% in Wednesday's session, falling from a prior close of $4.14 to about $2.89.
  • The primary catalyst was a deeply dilutive $1.31 million registered direct offering priced at $2.00 per share — a steep discount to the prior close.
  • The financing leaned on a "financial hardship" exemption, underscoring the company's serious liquidity strain and a going-concern warning flagged in recent quarters.
  • The drop also reflects a "buy the rumor, sell the news" unwind after a speculative rally tied to a planned pivot into defense technology.
  • Elevated volume and extreme intraday swings signal heavy retail-driven, momentum-style trading rather than a fundamental re-rating.

Opening Summary

IM Cannabis Corp. (IMCC), a medical cannabis operator with businesses in Israel and Germany, saw its shares sink sharply on Wednesday after the company priced a small but heavily dilutive stock offering well below the market. The stock closed the prior session at $4.14 and was trading around $2.89 by mid-afternoon, a decline of roughly 30.19%, or about $1.25 per share. The sell-off was driven by a combination of the discounted equity raise, renewed concerns about the company's balance sheet, and a pullback following days of speculative gains tied to its announced foray into the defense and unmanned aerial systems sector.

Dilutive Direct Offering Sparks the Sell-Off

The immediate trigger for Wednesday's decline was the pricing of a registered direct offering of 655,000 common shares at $2.00 per share, raising approximately $1.31 million in gross proceeds before expenses. Because the offering price represented a discount of more than 50% to the prior closing level, the deal carried a sharply dilutive signal for existing holders. The company said net proceeds would fund working capital and general corporate purposes, including the evaluation of additional business opportunities.

Critically, the financing was undertaken under a financial hardship exemption, a designation that requires a determination that the company is in serious financial difficulty. That framing reinforced investor concerns about IMCC's liquidity position, which had already been flagged through a going-concern warning and a series of small, high-cost convertible note raises in recent weeks. The market's reaction — a double-digit percentage decline on very heavy turnover — reflected the message that the company needs to raise capital at unfavorable terms.

Sell-the-News After the Defense Pivot Rally

The offering landed just as IMCC formally announced a non-binding letter of intent to acquire 51% of Space Defense Innovations LLC, a Polish entity operating in the tactical unmanned aerial systems market through its BlueAero Group subsidiary. The proposed pivot away from core cannabis operations had ignited a speculative frenzy earlier, with the stock surging dramatically on extremely heavy volume before pulling back.

Wednesday's action suggested a classic "sell the news" dynamic. With the defense deal now formalized — but still non-binding and subject to due diligence, definitive agreements, and regulatory approvals — traders who had chased the stock into its spike appeared to take profits, and the concurrent discounted offering gave them an additional reason to exit. The acquisition, while strategically notable, does not change the near-term financial picture, and the market refocused on execution risk and dilution.

Reverse Split and Nasdaq Compliance Backdrop

The volatility is occurring against a backdrop of corporate restructuring. IMCC completed a 1-for-30 reverse stock split in late August to support Nasdaq minimum bid price compliance, and it has disclosed plans to sell its European-focused assets while retaining its Israeli medical cannabis operations. These measures, combined with the going-concern disclosure, have kept the stock's beta and trading range elevated, leaving it prone to outsized moves in both directions on company-specific headlines.

Market Context and Trading Activity

Wednesday's decline was accompanied by unusually heavy trading activity, with millions of shares changing hands — far above the stock's typical daily turnover. The price action was highly volatile, with a wide intraday range that underscored the influence of short-term, momentum-oriented traders. The move was company-specific rather than a reflection of broad market weakness, as the cannabis and defense sectors showed no comparable systemic sell-off during the session.

Technically, the stock broke decisively below the prior session's close and slid through the psychologically significant $3.00 level, erasing a meaningful portion of the previous week's explosive rally. Despite the sharp drop, shares remain well above the 52-week low near $1.55, but they also trade far below the recent spike high reached during the initial defense-deal speculation.

What Comes Next for IMCC

Investors will be watching several developments closely. The direct offering is expected to close on or about September 24, and its completion will add to the share count while providing limited near-term relief. The proposed Space Defense Innovations transaction remains contingent on due diligence and the negotiation of definitive agreements, with no assurance of closing. The company's next earnings report is anticipated in November, when management's commentary on liquidity, the status of the European asset sale, and any progress on the defense pivot will be closely scrutinized.

Key risks include continued dilution from future financings, the possibility that the defense acquisition does not close, ongoing Nasdaq listing compliance concerns, and the company's persistent operating losses. Given the elevated volatility and the stock's thin, retail-heavy shareholder base, further sharp swings are likely in both directions.

Trending AI Robots

For traders seeking a more systematic approach to fast-moving markets, Tickeron's Trending AI Robots page offers a curated selection of AI-driven trading bots. Tickeron provides hundreds of AI trading bots covering thousands of tickers, but only the strongest performers under current market conditions are featured in this section. Bots vary by strategy, timeframe, performance metrics, and the symbols they trade, allowing users to explore a range of data-driven approaches. Consider reviewing the Trending AI Robots to see which strategies are currently leading the market.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Related Ticker: IMCC

Contributor

Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.


Momentum Indicator for IMCC turns positive, indicating new upward trend

IMCC saw its Momentum Indicator move above the 0 level on September 18, 2026. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 88 similar instances where the indicator turned positive. In 76 of the 88 cases, the stock moved higher in the following days. The odds of a move higher are at 86%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 58 of 68 cases where IMCC's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 85%.

Following a +159.51% 3-day Advance, the price is estimated to grow further. Considering data from situations where IMCC advanced for three days, in 166 of 196 cases, the price rose further within the following month. The odds of a continued upward trend are 85%.

Bearish Trend Analysis

The 10-day RSI Indicator for IMCC moved out of overbought territory on August 27, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 16 similar instances where the indicator moved out of overbought territory. In 16 of the 16 cases, the stock moved lower in the following days. This puts the odds of a move lower at 90%.

The Moving Average Convergence Divergence Histogram (MACD) for IMCC turned negative on August 28, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 37 similar instances when the indicator turned negative. In 33 of the 37 cases the stock turned lower in the days that followed. This puts the odds of success at 89%.

IMCC moved below its 50-day moving average on August 27, 2026 date and that indicates a change from an upward trend to a downward trend.

The 10-day moving average for IMCC crossed bearishly below the 50-day moving average on September 09, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 10 of 10 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 90%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where IMCC declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.

IMCC broke above its upper Bollinger Band on September 22, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

The Aroon Indicator for IMCC entered a downward trend on September 22, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of 24 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.949) is normal, around the industry mean (43.618). P/E Ratio (0.000) is within average values for comparable stocks, (141.316). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.181). Dividend Yield (0.000) settles around the average of (0.005) among similar stocks. P/S Ratio (0.011) is also within normal values, averaging (178.797).

The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron Price Growth Rating for this company is 98 (best 1 - 100 worst), indicating slightly worse than average price growth. IMCC’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron PE Growth Rating for this company is 100 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. IMCC’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 82, placing this stock worse than average.

Notable companies

The most notable companies in this group are Teva Pharmaceutical Industries Limited (NYSE:TEVA), ZOETIS (NYSE:ZTS), Elanco Animal Health (NYSE:ELAN), BioCryst Pharmaceuticals (NASDAQ:BCRX), Bausch Health Companies (NYSE:BHC), Tilray Brands Inc. (NASDAQ:TLRY), Canopy Growth Corp (NASDAQ:CGC), Aurora Cannabis (NASDAQ:ACB), Journey Medical Corp (NASDAQ:DERM).

Industry description

A generic drug contains the same chemical substance as a drug that was originally protected by patents. Generic drugs are generally sold at cheaper price points, compared to name-brand pharmaceuticals, after patents for the more expensive drugs lapse. The generic drug industry has created a major market, thanks to the lower pricing. According to the Center for Justice and Democracy at New York Law School, 80 percent of all drugs prescribed are generic, and generic drugs are chosen 94 percent of the time when they are available. But their manufacturers must be able to prove to the FDA that they can be effective substitutes for the original drugs. Some of the major generic drug makers include Zoetis, Inc., Allergan plc and Mylan N.V.

Market Cap

The average market capitalization across the Pharmaceuticals: Generic Industry is 4.11B. The market cap for tickers in the group ranges from 2.12K to 66.17B. MKGAF holds the highest valuation in this group at 66.17B. The lowest valued company is CANQF at 2.12K.

High and low price notable news

The average weekly price growth across all stocks in the Pharmaceuticals: Generic Industry was 4%. For the same Industry, the average monthly price growth was -5%, and the average quarterly price growth was 44%. IMCC experienced the highest price growth at 154%, while SBFM experienced the biggest fall at -13%.

Volume

The average weekly volume growth across all stocks in the Pharmaceuticals: Generic Industry was 55%. For the same stocks of the Industry, the average monthly volume growth was 58% and the average quarterly volume growth was 30%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 52
P/E Growth Rating: 63
Price Growth Rating: 56
SMR Rating: 87
Profit Risk Rating: 81
Seasonality Score: -15 (-100 ... +100)
View a ticker or compare two or three
IMCC
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

Industry PharmaceuticalsGeneric

Industry
N/A
Address
Central District
Phone
+972 773603504
Employees
44
Web
https://www.imcannabis.com
Interact to see
Advertisement
SMCI shares are plunging approximately 26% in Friday premarket trading, extending sharp after-hours losses from Thursday's session close of $30.79. The primary catalyst is a federal indictment unsealed March 19, 2026, charging three individuals associated with Super Micro — including a company co-founder — with conspiring to illegally export billions of dollars in AI server technology to China.
PL shares are surging approximately 19% in premarket trading on March 20, 2026, building on an 8.67% gain during the regular session on March 19. The primary catalyst is a blowout Q4 fiscal year 2026 earnings report released after the close on March 19, with quarterly revenue of $86.8 million — an 11.55% beat against consensus expectations of $77.81 million.
Unusual Machines (UMAC) is trading down approximately -8.60% in premarket on March 20, 2026, extending losses from the prior session. The primary catalyst is a proposed public stock offering announced after the market close on March 19, 2026, raising dilution concerns among investors.
FDX surged approximately 7% in premarket trading on March 20, 2026, moving from the prior session close of $356.11 to around $381. The primary catalyst is a blowout fiscal Q3 2026 earnings report, with adjusted EPS of $5.25 — beating Wall Street's consensus estimate of $4.13 by more than 27%.
Kingsoft Cloud Holdings Limited (KC) shares plunged about 9% in the most recent session, extending a sharp pullback after a recent rally. The selloff reflects mounting concerns around profitability, with the company still loss-making and showing weak multi-year revenue growth.
BAK shares fell roughly 11% in the latest trading session, marking a sharp single-day drop for the Brazilian petrochemical producer The decline comes amid persistent concerns about high leverage, a weaker credit profile, and soft petrochemical margins in a challenging macro environment for chemicals​
INSM shares are surging approximately +10% in premarket trading on Monday, March 23, 2026, from a prior close of $136.00, placing the premarket price near $149.60. The primary catalyst is the release of positive topline results from the Phase 3 ENCORE trial of ARIKAYCE® in patients with newly diagnosed or recurrent MAC (Mycobacterium avium complex) lung disease — a readout Insmed had flagged as expected in "March or April 2026".
CF shares are trading approximately -6% lower in Monday's premarket session, dropping from a Friday close of $124.90 to approximately $117.41. Primary catalyst: President Trump announced a five-day pause on strikes against Iranian energy infrastructure following "very good" diplomatic signals, triggering a sharp unwind of the geopolitical risk premium embedded in fertilizer stocks.
APGE shares surged approximately 16% in premarket trading on March 23, 2026, after the company announced positive 52-week data from Part A of its Phase 2 APEX clinical trial. The primary catalyst is a highly anticipated clinical readout showing that zumilokibart (APG777) delivered durable and deepening responses in patients with moderate-to-severe atopic dermatitis at both every 3-month and 6-month dosing intervals.
Shares of VALN are plummeting approximately 35% in Monday's session, from a Friday close of $10.66 to roughly $6.93, in heavy volume trading. The primary catalyst is the release of Phase 3 VALOR trial topline results for Valneva's Lyme disease vaccine candidate, co-developed with PFE (Pfizer) — results that showed strong clinical efficacy but failed to meet the pre-determined statistical criterion for the primary endpoint.
AXTI is surging approximately +11.00% in Monday's session, trading near $60.21, up from a prior closing price of $54.24. The move extends the stock's post-earnings rally that began last Thursday when shares jumped more than 19% following AXT's Q4 2025 results.
Tower Semiconductor (TSEM) shares are surging approximately +10% intraday on Monday, March 23, trading around $180, up from the previous close of $163.63 on March 20, 2026. The primary catalyst is the opening day of APEC 2026 in San Antonio, Texas, where Tower Semiconductor is presenting its newly unveiled Gen3 BCD power management platform designed to address escalating AI data center power demands.
CD is indicated down about 17% in premarket trading after the latest completed session, pointing to a sharp negative market reaction heading into the open. The stock’s weakness comes against a backdrop of lingering uncertainty following its privatization and delisting process from Nasdaq, which has left limited liquidity and a thinner news flow around the name.
SEDG is indicated down roughly 9% in premarket trading, following a strong advance in the prior regular session. The pullback comes after shares rallied on optimism around new product launches and an analyst upgrade, leaving the stock vulnerable to profit-taking and volatility.
NTGR shares surged approximately 11% in premarket trading on March 24, 2026, building on a roughly 20% overnight jump in the prior session. The primary catalyst is a landmark Federal Communications Commission (FCC) ruling that prohibits all imports of consumer routers manufactured overseas, citing national security concerns.
ANNA is surging approximately +20.00% in Tuesday's premarket session, rebounding sharply from Monday's -22.84% decline. The primary catalyst remains the ongoing U.S.-Iran military conflict, which disrupted Qatari LNG exports and drove European benchmark natural gas prices to multi-year highs.
Concentrix Corporation (CNXC) shares are falling approximately 11% in Tuesday's premarket session after the company released its fiscal Q1 2026 earnings report before market open. Adjusted diluted EPS came in at $2.61, missing the Wall Street consensus estimate of approximately $2.64.
Shares of Karyopharm Therapeutics (KPTI) are trading approximately 12% lower in Tuesday's premarket session, with the previous close at $7.63. The primary catalyst is the March 24 release of topline Phase 3 SENTRY trial data, in which the company met only one of two co-primary endpoints.
IBRX shares are down approximately 23% in Tuesday's session, trading near $7.24 after closing at $9.40 on Monday, March 23. The sharp decline follows an 11%+ surge in the prior session, with profit-taking and valuation pressure cited as primary triggers.
Shares of Circle Internet Group (CRCL) are down approximately 9% in Tuesday morning trading, extending a pullback from recent multi-month highs above $126. The primary catalyst appears to be a broad crypto-sector risk-off wave, with Bitcoin sliding below $69,000 and the Fear & Greed Index dropping to extreme fear territory.